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Abstract 
 
Background: The hallmarks of type 2 diabetes are both insulin resistance and insulin 
insufficiency. Obesity is a high risk factor of type 2 diabetes. As an endocrine organ, adipose 
tissue can secrete a large number of adipokines that regulate metabolism and inflammation. It 
was shown that pro-inflammatory adipokines are elevated in obesity associated with insulin 
resistance. Obesity has been shown to induce ER stress in liver causing insulin resistance. Our 
previous work shows that ER stress deteriorates adipokines secretion from adipocytes. 
Incretin analogues and DPP-4 inhibitors are now used in the clinic to treat patients suffering 
from type 2 diabetes. Incretins can regulate lipid synthesis and glucose uptake in adipocytes. 
However, no data are available regarding whether incretins affect the production and secretion 
of adipokines from adipose tissue. The aim of this study was therefore to test if incretins and 
DPP-4 inhibitors regulate the secretory function of adipocytes. 
Material and Methods: After differentiation, 3T3-L1 adipocytes were incubated in the 
presence of GLP-1(7-36), GLP-1(9-36), GLP-1 receptor agonist (Exendin-4) and DPP-4 
inhibitor, Sitagliptin (DPP-4i) individually or in combinations under ER stress or homeostasis. 
The secretion of adipokines into the supernatant was measured by multiplexing. The induction 
of ER stress was confirmed by Western blotting.   
Results: ER stress elevated the accumulation of the proinflammatory cytokines KC 
(keratinocyte chemoattractant) and IL-6 (Interleukin-6) but reduced adiponectin 
concentrations. GLP-1(7-36), Exendin-4 and GLP-1(9-36) affected the accumulation of 
adipokines under homeostasis and ER stress in a similar manner. They increased adiponectin 
and KC under homeostasis but reduced KC under ER stress. DPP-4i increased pro-
inflammatory cytokines KC and IL-6 under homeostasis.  
Discussion and conclusion: In the present study, we show that incretins and the inhibitor 
Stagliptin regulate the secretory function of adipocytes. Importantly, Stagliptin increases pro-
inflammatory cytokines without changing secretion of adiponectin or leptin. This could 
explain why patients treated with Stagliptin have a higher risk for infection. Therefore, a 
possible immune-modulatory role of DPP-4i should be taken into account for clinical use of 
these compounds.  
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1 Introduction 
 
1.1 Diabetes 
1.1.1 The history of diabetes 
 
Since a long time diabetes is recognized as a systemic complex disease. As summarized in the 
education web site of the Canadian Diabetes Association [2], as early as 1552 BC, Egyptian 
physician Hesy-Ra mentioned a disease that is associated with “passing of too much urine”. In 
120 AD the word “diabetes” was first used by Aretaeus, a Greek, to describe the symptoms of 
patients having a large amount of urine flowing. In the 17th century, Professor Thomas Willis 
of Oxford University used the smell and taste of urine samples from patients to determine 
whether they were diabetic. If the urine had a sweet taste, he would diagnose the patient with 
diabetes mellitus. In 1901, American pathologist Eugene Opie established a connection 
between the failure of the islets of Langerhans in the pancreas and the occurrence of diabetes. 
In 1921, Dr. Frederick Banting led the discovery of insulin that was extracted from pancreas 
and he was awarded the Nobel Prize in Physiology or Medicine in 1923. Since the discovery 
of insulin, diabetes has become a treatable disease. In 1936, Sir Harold Himsworth of the 
University College Hospital in London found that diabetes falls into two types based on 
“insulin insensitivity”. This discovery later lead to the diabetes classifications of type 1 and 
type 2 in 1959. Diabetes mellitus now is defined as a syndrome of impaired carbohydrate, fat 
and protein metabolism characterized by high blood glucose and dyslipidemia. It is caused by 
either absolute lack of insulin or by decreased sensitivity of insulin target tissues in 
combination with relative hypoinsulinaemia [3].  
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1.1.2 Classification of diabetes 
 
According to the American Diabetes Association there are four types of diabetes mellitus by 
etiological classification: type 1 diabetes, type 2 diabetes, other specific types of diabetes 
(genetic defects in insulin action, drug or chemical-induced diabetes, infection-induced 
diabetes and so on) and gestational diabetes [4] (see Table. 1). 
1. Type 1 diabetes  
1.1. Immune-mediated 
1.2. Idiopathic 
2.Type 2 diabetes 
3. Other specific types 
3.1. Genetic defects of β-cell function 
3.2. Genetic defects in insulin action 
3.3. Diseases of the exocrine pancreas 
3.4. Endocrinopathies 
3.5. Drug- or chemical-induced 
3.6. Infections 
3.7. Uncommon forms of immune-mediated diabetes 
3.8. Other genetic syndromes sometimes associated with diabetes 
4. Gestational diabetes mellitus (GDM) 
Table 1: Etiological classification of diabetes mellitus. Modified from [5]. 
 
1.1.3 Type 2 diabetes 
 
90% of all diabetes cases are type 2 diabetes [6]. Proper regulation of normal blood glucose 
levels depends on the balance of sufficient insulin production/secretion relative to insulin 
sensitivity in liver, muscle and adipose tissue. The hallmark of type 2 diabetes is the 
combined occurrence of both insulin resistance and insulin insufficiency. Diabetes eventually 
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develops when under prolonged persisting insulin resistance the pancreatic β-cells fail to 
adapt, not producing sufficient insulin for normal regulation [7]. 
The major risk factor for type 2 diabetes is obesity [8]. However, a conclusive mechanistic 
link between obesity, insulin resistance and the development of the metabolic syndrome is 
still missing. There are genetic and environmental components in the events leading to β-cell 
failure. Chronic exposure of pancreatic islets to elevated nutrients induces β-cell dysfunction 
and death. It was concluded that β-cell dysfunction is a consequence of ‘glucolipotoxicity’ 
rather then exposure to a single nutrient alone [9]. 
 
1.1.4 Insulin and insulin resistance 
 
1.1.4.1  Insulin and insulin signal transduction  
 
The production of insulin exclusively occurs in pancreatic β-cells [10]. Mature insulin 
accumulates within vesicles in the cytoplasm of pancreatic β-cells and is secreted upon 
glucose stimulation. The main function of insulin is to lower circulating blood glucose levels, 
which is mainly mediated by insulin-stimulated glucose uptake into skeletal muscle (and to a 
minor part adipose tissue and even kidney) and by insulin-induced suppression of glucose 
release (gluconeogenesis and glycogenolysis) from the liver. Inhibition of free fatty acid (FFA) 
release from adipose tissue and stimulation of protein synthesis in skeletal muscle are other 
important metabolic functions of insulin. 
When bound to insulin, insulin receptors autophosphorylate and transfer the signal down 
stream by phosphorylating and attracting insulin receptor substrates (IRS). Tyrosine-
phosphorylated IRS contain many docking sites for downstream signalling components such 
as phospatidylinositol 3-kinase (PI3-K). Protein kinase B (PKB) and protein kinase C (PKC) 
isoforms λ and ζ, which are downstream factors of PI3-K, are then activated and contribute to 
regulating glucose homeostasis [11] (Figure 1). 
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1.1.4.2  Insulin resistance 
 
Insulin resistance was discovered 60 years ago in 1939 by Sir Himsworth. He set forth the 
hypothesis that insulin deficiency should not be the only reason for the development of 
diabetes. He concluded that insensitivity of the tissues to insulin may also contribute to the 
process [12]. 10 years later it was shown that normal or elevated insulin levels can be present 
in diabetic patients [13]. Today, insulin resistance is defined as insufficient action of insulin in 
target tissues and it is one of the major factors leading to the development of type 2 diabetes 
[14]. 
At the molecular level insulin resistance is due to blocked insulin signal transmission [15, 16]. 
In particular, phosphorylation of IRS on specific serine residues inhibits tyrosine 
phosphorylation of IRS by decreasing affinity for the insulin receptor kinase, resulting in 
reduced transmission of the insulin signal. Many factors contribute to this blocking process 
such as cytokines like tumour necrosis factor-α (ΤΝF-α) [17],  FFAs [18], c-Jun N-terminal 
kinase (JNK) [19] and nuclear factor-kappa B (NF-κB) [20].  
 
Insulin / IGF-1
 
 
 
 
 
 
 
 
 
 
 
 
   Figure 1: The insulin signalling network. Kindly provided by Markus Niessen and Stephan Wüest.  
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1.2 Adipose tissue 
 
Adipose tissue (AT) is a loose connective tissue containing lipid-laden adipocytes, 
macrophages, fibroblasts, blood cells, endothelial cells and adipose precursor cells [21]. 
Adipocytes comprise around 35% to 70% of adipose tissue’s mass in adults. The lipid 
droplets of adipocytes contain a mixture of neutral fats, triglycerides, fatty acids, 
phospholipids and cholesterol. 
 
1.2.1 Classification and function of adipose tissue 
 
According to the biochemical and functional characteristics, AT is classified into two types: 
brown adipose tissue (BAT) and white adipose tissue (WAT) [22].  
BAT is rich in mitochondria and lysosomes and responsible for thermogenesis by transferring 
energy from food into heat [23]. In the neck and interscapular region of newborn, BAT is well 
developed, but the distribution in childhood is limited and only a small amount is present in 
adults. This may be because the need for thermogenesis is reduced due to clothing and indoor 
life [24].  
For a long time, it was believed that the function of WAT was limited to storing excess 
energy as triacylglycerol (TG) in large unilocular droplets, and its release in form of free fatty 
acids for oxidation by skeletal muscle and other tissue [24]. The discovery of leptin and of its 
secretion from adipose tissue in 1994 extended the understanding of adipose tissue function 
[25]. In addition to energy storage, the endocrine function of WAT is now well recognized 
and known to play a central role in whole body homeostasis [26]. At the same time, the 
finding that adipoytes themselves express receptors for most adipokines reveals that there are 
both local and systemic controls employed for the regulation of metabolic balance [27].  
 
1.2.2 Adipokines 
 
As already indicated above, adipose tissue functions as an endocrine organ to regulate the 
metabolic balance of the body by secreting a great number of bioactive mediators, which are 
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 called adipokines [16, 28]. Table 2 summarizes the main adipokines and their known 
functions. Among these, we pick some factors for more in-depth description, because they 
have close relationship to the development of diabetes as described below. 
 
1.2.2.1  Leptin 
 
Leptin was discovered in 1994 [25]. It is produced by differentiated adipocytes [29]. The 
plasma concentration of leptin is directly related to the severity of obesity [30]: an increased 
leptin level is found when fat mass is increased.  
Leptin regulates food intake (appetite) and energy homeostasis [31, 32]. It improves insulin 
sensitivity of liver and skeletal muscle and it was shown that mice lacking white adipose 
tissue suffer from severe hepatic and muscle insulin resistance with increased TG storage in 
these tissues [33]. Furthermore, leptin also plays an important role in pancreatic β-cells. It was 
shown that leptin inhibits insulin secretion in lean animals. However, when body fat increases, 
leptin protects β-cells and improves β-cell function [34]. The concept of “adipo-insular axis” 
was introduced based on the finding that insulin stimulates leptin biosynthesis and secretion 
from adipose tissue and it is a classical endocrine feedback loop [35]. However, in obesity 
leptin fails to reduce body weight, although both leptin and leptin receptor levels are elevated, 
suggesting “leptin resistance”. 
 
1.2.2.2  Adiponectin 
 
In 1995, an adipose-secreted protein was first identified and named adiponectin, Acrp 30 or 
adipoQ [36]. Its concentration in circulation is reduced under obesity [37], insulin resistance 
[38] and type 2 diabetes [39]. 
There are three forms of adiponectin in circulation: trimers, hexamers and high-molecular 
weight (HMW) 12-18 mers [40]. The HMW are the biologically active forms of the hormone 
[41] and they are related to insulin sensitivity and development of the metabolic syndrome 
[42]. Two similar case studies have suggested that people with high adiponectin concentration 
have lower risk to develop type 2 diabetes compared to those with low adiponectin 
concentration [43], [44]. In addition to improving insulin sensitivity, adiponectin can reduce 
 - 9 - 
 the inflammatory response induced by tumor necrosis factor-α (TNF-α) [45]. Οn the other 
hand, TNF-α and interleukin-6 (IL-6) repress adiponectin expression in human adipocytes[46] 
 
1.2.2.3  IL-6 
 
IL-6 is a cytokine produced by several cell types such as monocytes, fibroblasts, endothelial 
cells [47], adipocytes [48] and skeletal muscle cells [49]. Under normal condition, adipose 
tissue contributes to 15-30% of circulating IL-6 [50]. However, since adipose tissue contains a 
number of cell types other than adipocytes, the IL-6 secreted from adipose tissue may be 
derived from monocytes/macrophages, or endothelial cells [51]. 
IL-6 participates in many physiological events. It acts as a differentiation factor for B cells 
promoting their differentiation into antibody producing cells [52]. It has been reported that IL-
6 induces proliferation of hybridoma/plasmacytoma/myeloma cells, IL-2 production, 
cytotoxic T cell differentiation and neuronal differentiation. It regulates the immune system, 
the hematopoietic system and controls inflammatory response [47]. 
IL-6 plays different roles in insulin action and insulin resistance. Studies have shown that IL-6 
elevates insulin-dependent glucose uptake and glucogen synthesis in skeletal muscle. In 
adipocytes, effects of IL-6 are complex and context dependent. Long term studies indicated 
that IL-6 represses insulin signalling by reducing expression of IRS1, thereby impairing 
insulin-stimulated glucose transport [53]. However, infusion of IL-6 at physiological 
concentrations increased adipose tissue glucose uptake in humans [54]. In hepatocytes IL-6 
induces insulin resistance [55]. A study by Ellingsgaard and co-workers indicated that IL-6 
regulates pancreatic α-cell mass and β-cell function [56]. It also regulates expression of 
proglucagon mRNA and the secretion of glucagon.  
 
1.2.2.4  TNF-α 
 
TNF-α is a proinflammatory cytokine. It is produced by numerous cell types, but mainly by 
macrophages and lymphocytes. In WAT, both adipose cells and cells of the stromal vascular 
fraction can produce TNF-α . Studies have shown that the expression of TNF-α in adipose 
tissues is elevated in obesity. Upon weight loss, TNF-α is decreased and improvement of 
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insulin sensitivity is observed [57]. Both TNF-α and TNF-α receptor-deficient mice are 
protected from obesity-induced insulin resistance under high fat diet [58] suggesting this 
cytokine may molecularly link obesity and insulin resistance [59].  
 
1.2.3 Obesity and insulin resistance 
 
Although the so called body mass index (BMI) overestimates fatness in people who are 
muscular or athletic, it is still used to indicate if people are overweight, obese, underweight or 
normal. The World Health Organization (WHO) calls a person obese if he or she has a BMI > 
30. Obesity results when energy intake exceeds energy expenditure. Adipose tissue mass 
expands by increasing size of existing fat cells (hypertrophy) and increasing the fat cell 
number (hyperplasia) [21]. Excess energy is initially stored through hypertrophy and cells can 
become up to four times larger than normal due to excess accumulation of lipids. Only when 
the existing fat cells reach a critical size, hyperplasic growth of adipocytes occurs [61]. 
Among the risk factors that are believed to contribute to the development of insulin resistance, 
obesity is the most important. More than 80% of subjects with type 2 diabetes are overweight 
[62]. However, not all obese subjects develop type 2 diabetes. 
 
1.2.3.1 Altered production of adipokines and insulin resistance 
 
A hallmark of obesity is chronic low-level systemic inflammation [63]. Under obesity, 
circulating levels of inflammatory markers and the expression of inflammation-related 
adipokines generally rises (adiponectin, which has anti-inflammatory action is an exception). 
Altered adipokine production contributes to insulin resistance. For example, increased levels 
of TNF-α activate IKKβ leading to phosphorylation of IRS1 on serine and blocking of insulin 
signal transduction [64]. Suppressors-of-cytokine-signalling (SOCS) proteins which can be 
elevated by cytokines under obesity were shown to inhibit insulin signalling by preventing the 
binding of IRS to the tyrosine-phosphorylated insulin receptor [65]. Moreover, the change of 
adipokine secretion under obesity not only influences insulin sensitivity in adipocytes but also 
affects other organs of the body. For example, elevated IL-6 and TNF-α play a role in 
development of non-alcoholic fatty liver disease (NAFLD) that contributes to hepatic insulin 
resistance [66-68]. 
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1.2.3.2  Endoplasmic reticulum (ER) stress, the UPR and insulin resistance 
 
The Endoplasmic reticulum (ER) is a membrane–surrounded intracellular compartment and 
stretches from the nuclear envelop in all eukaryotic cells [69]. It is the site of synthesis, 
folding and sorting of transmembrane and secretory proteins [70]. The ER is an indispensible 
compartment for lipid bilayer assembly and the storage of calcium ions (Ca2+) [71, 72]. 
Under conditions that impair ER function, proteins are unable to fold properly and accumulate 
in the ER lumen, this causes ER stress. To deal with ER stress, cells have evolved a special 
coping response called unfolded protein response (UPR) (reviewed by [73]). The UPR 
maintains ER homeostasis by increasing the protein folding capacity through increasing the 
size of the ER and inducetion of ER-resident molecular chaperones as well as reducing 
loading of the ER through suppression of transcription and translation. The ER clears the 
unfolded proteins by ER-associated degradation (ERAD) [74].  
There are three transmembrane proteins acting as ER sensors. They are type I transmembrane 
protein kinase endoribonuclease inositol-requiring protein-1 (IRE1), protein kinase-like ER 
kinase (PERK) and type II transmembrane protein activating transcription factor 6 (ATF6) 
(reviewed by [75]). Under physiological conditions, IRE1, PERK and ATF6 are inhibited 
when bound to the ER chaperone glucose-regulated protein 78 (Grp78, also called Bip). 
Under ER stress, Grp78 is released from these three sensors, resulting in oligomerization of 
IRE1 and PERK and translocation of ATF6 to Golgi complex and activation. 
The IRE1 pathway regulates chaperone production, ERAD and hepatic lipogenesis [76]. It 
also recruits tumour necrosis factor receptor–associated factor 2 (TRAF2) and activates c-Jun 
N-terminal kinase (JNK) [77]. Activation of PERK phosphorylates eIF2α and results in 
downregulation of overall translation [78]. The ATF6-dependent pathway induces the 
expression of genes encoding molecular chaperones like Grp78 and Grp94 (Figure 2). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Schematic representation of the UPR. Adapted from [1]. 
 
 
In 2004, Ozcan et al. reported that ER stress links obesity and type 2 diabetes. These authors 
showed that ER stress occurs in liver and fat of high fat diet fed ob/ob mice. Activation of the 
UPR in response to ER stress was shown to inhibit IRS1 via JNK-dependent serine 
phosphorylation leading to reduced insulin sensitivity and development of insulin resistance 
in liver [77]. Our unpublished results show that ER stress not only impairs insulin signalling 
at different levels in adipocytes (insulin receptor, IRS and PKB (Figure 3)) but also alters the 
secretion of adipokines (elevates IL-6 and decreases leptin (Figure 4)) which are known to 
contribute to systemic inflammation and insulin resistance.   
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Figure 3: ER stress represses insulin signalling at different levels in 3T3-L1 adipocytes. Tunicamycin (Tu) 
or Thapsigargin (Thap) were included in the culture medium of 3T3-L1 adipocytes for 24 h. Before insulin 
(100nM) stimulation, cells were starved for 2 h. The stimulation was 5, 10, 15, 20 or 30 min.  Cells were lysed 
afterwards. The Western blot shows expression and activity state of the IR, Akt/PKB, ERK1/2. Expression of 
actin was assessed as a control. The induction of ER stress was monitored using an antibody against Grp78.  
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Figure 4: 3T3-L1 adipocytes secrete more IL-6 but less leptin under ER stress. 3T3-L1 adipocytes were 
incubated in the presence of thapsigargin (Thap, 300nM) for 16 hours. After three washes with PBS, Kreb’s 
Ringer buffer containing 1% BSA but without substance was added to the cells for 90 min. Supernatants were 
collected and the accumulated IL-6 and leptin were measured by mutiplex analysis. Data from one representative 
experiment are shown relative to cellular protein content.  
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1.3 Incretins 
 
The history of the incretin concept can be traced back to one century ago [79]. Early in 1902, 
Bayliss and Starling showed that acid extracts of intestinal mucosa contain a factor that 
stimulates exocrine secretion of pancreas and they named it secretin [80]. This report 
represents the birth of gastrointestinal endocrinology and challenged the traditional “nerves 
doctrine” that the functions of the body were controlled solely by nerves. After the report of 
secretin, numerous experiments have been performed to test the effect of it on fasting or 
elevated blood glucose levels of animal or humans. In 1932, La Barre for the first time used 
the term incretin to indicate the substance extracted from the upper gut mucasa, which 
produces hypoglycemia and does not stimulate pancreatic exocrine secretion [81]. In 1964, 
with radio-immunologic techniques the incretin effect had been proved. It became obvious 
that the insulin secretory responses after oral glucose ingestion exceeded those elicited by the 
intravenous administration of an equal amount of glucose [82], [83]. In 1970, glucose-
dependent insulinotropic polypeptide (GIP) was first isolated by Brown [84] [85]. In 1985, 
another intestinal peptide glucagon-like peptide-1 (GLP-1) was identified during the cloning 
of pre-proglucagon [86].  
 
1.3.1 GIP 
 
GIP is a 42-aminoacid hormone and synthesised in duodenal and jejunal enteroendocrine K 
cells in the proximal small bowel [87]. The secretion of GIP follows in response to oral 
glucose or mixed meals. It has weak effects on gastric acid secretion but shows potent 
insulinotropic action in human beings [88]. In addition to enhancing insulin release, GIP was 
shown to stimulate proinsulin gene transcription and translation [89]. It also stimulates 
differentiation, proliferation and survival of pancreatic β-cells [90]. Moreover, it was shown 
that GIP can reduce hepatic glucose production [91], promote glucose uptake in isolated 
muscle [92] and adipocytes [93]. GIP has also been shown to reduce glucagon-stimulated 
lipolysis [94] and to stimulate the synthesis and secretion of lipoprotein lipase in rat adipose 
tissue explants [95]. The finding that GIP receptor-deficient (GIPR−/−) mice were resistant to 
the development of obesity when on a high-fat diet [96] supports the view that GIP plays a 
crucial role in the development of obesity due to chronic over nutrition.  
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1.3.2  GLP-1  
 
The biologically active forms of GLP-1 are GLP-1(7-36) [97] and GLP-1(7-37) [98]. Also 
GLP-1(7-37) has insulinotropic activity [98], but GLP-1(7-36) is the most active isoform [99]. 
Food intake in the gut causes GLP-1 production and release from small intestinal L-cells. It 
stimulates insulin secretion and slows gastric emptying [100]. Like GIP, GLP-1 also can 
promote pancreatic β-cell growth and survival [101], [102].  
GLP-1 receptors can be found on many cells throughout the body, especially β-cells, liver, 
and neurons [103]. GLP-1 acts directly through the cAMP → protein kinase A (PKA) 
pathway to enhance and sensitize β-cells to glucose-stimulated insulin secretion [104]. GLP-1 
(or its agonist exendin-4) also increases pancreatic β-cell survival, leading to an increase of β-
cell mass. PKA-mediated activation of the transcription factor cAMP responding element 
binding protein (CREB) plays an important role in GLP-1 action in β-cells by increasing the 
expression of the glucose transporter (GLUT)-2, insulin, glucokinase, and PDX-1 [105]. 
CREB phosphorylation increased the induction of IRS2 in islets. Tyrosine phosphorylated 
IRS2 activates the phosphoinositide-3 (PI3) kinase and protein kinase B (PKB, Akt) cascade 
and is fundamental to the proper regulation of β-cell survival and growth [106]. 
There are also reports showing that GLP-1 improves insulin-controlled glucose homeostasis 
in myotubes [107], [108], isolated rat adipocytes [109] and 3T3-L1 adipocytes [110]. 
Moreover, a study by the group of Ning [111] revealed that GLP-1 and exendin-4, can 
increase insulin receptor, IRS1 and GLUT4 expression levels in 3T3-L1 adipocytes. Exendin-
4 is a naturally occurring analog of GLP-1 [112] that binds and activates the GLP-1 receptor 
with the same potency as GLP-1 [113], [114]. GLP-1 receptors are found in specific nuclei 
within the hypothalamus [115]. Long-term exendin 4 treatment of Zucker rats (characterized 
by a deficient in leptin receptors in the brain) reduces food intake and decelerates weight gain 
[116]. 
Based on the observation that GLP-1(7-36) is rapidly degraded by dipeptidyl peptidase-4, 
(DPP-4) yielding the inactive GLP-1(9-36) form [117], DPP-4 inhibitors have been designed 
to increase endogenous GLP-1(7-36) levels. One of these inhibitors is sitagliptin. DPP-4- 
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deficient mice are healthy, fertile, and have improved metabolic function [118]. However, as 
reviewed in [119], treatment of patients with sitaglipin reduced hemoglobin A1c to 0.7% and 
therefore there is probably no additional metabolic benefit of sitagliptin treatment compared 
to other hypoglycaemic agents. No definite conclusions could be drawn from published data 
on sitagliptin effects on measurements of beta-cell function. In addition, DPP-4 is identical to 
CD26, a marker for activated T-cells [120]. It has been shown that DPP-4 has several effects 
on immune cells, including inhibition of cytokine production, and induction of transforming 
growth factor-ß secretion [121]. Although short term studies in patients did not show that 
inhibiting DPP-4 is toxic for the immune system, more information about long term treatment 
is necessary especially an analysis of possible adverse effects on parameters of immune 
function [119]. 
 
1.4 Aims of the project 
 
As introduced above, adipose tissue not only stores energy but also acts as an endocrine organ. 
It is an important hub in the regulation of blood glucose homeostasis and metabolic balance. 
Obesity-associated chronic inflammation and ER stress both contribute to the development of 
insulin resistance. While it is known that incretin hormones improve adipocyte glucose 
transport and lipogenesis, nothing is known about incretin hormones and the secretion of 
adipokines, especially under ER stress.  
The aim of this project was to study if and how incretins affect the secretion of selected 
adipokines from differentiated adipocytes under homeostasis and ER stress.  
 
1.5 Strategies 
 
For the purpose described above, differentiated 3T3-L1 adipocytes were cultured in the 
presence of different incretin substrates (GLP-1(7-36), GLP-1(9-36), and exendin-4) or DPP-
4i (Sitagliptin) under normal condition or ER stress. The accumulation of adipokines (IL-6, 
KC, leptin, adiponectin and TNF-α) in supernatants was assessed at different time points by 
multiplexing.  
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2 Materials and methods 
 
2.1 Culture and differentiation of 3T3-L1 fibroblasts into adipocytes  
 
3T3-L1 fibroblasts (purchased from ATCC, Manassas, USA) were cultured in DMEM (4.5 
g/L D-glucose) medium (Invitrogen) containing 10% (v/v) FCS, 100 U/ml penicillin, 100 
μg/ml streptomycin. Cells were incubated at 37 °C, under 5% CO2 in a humidified 
atmosphere. 3T3-L1 fibroblasts were plated on gelatin-coated 24 wells plates (TPP, 
Switzerland) and cultured in growth medium for two to three days to reach confluence. Then 
differentiation medium containing 0.5 mM isomethylbutylxanthine, 1 μM dexamethasone and 
1.7 μM insulin was added. Three days later, differentiation medium was replaced with growth 
medium, supplemented with 240 nM insulin for an additional 3 days. Cells were kept in 
DMEM (4.5 g/L D-glucose) containing 2% FCS for 5-7 days followed by DMEM (1.0 g/L D-
glucose), 2% FCS for 5 days prior to the start of an experiment. 
 
2.2 Induction of ER stress and incubation in the presence of substances  
 
ER stress was induced with either 10 μg/ml tunicamycin (TU) (Applichem) or 600 nM 
thapsigargin (Thap) (Calbiochem). TU was dissolved at 20 mg/ml in DMSO and Thap at 5 
mg/ml in Ethanol. Same amount of DMSO or Ethanol were used as the homeostasis condition. 
The induction of ER stress was assayed using an antibody against Grp78.  
Four different substances were used in combination with ER stressors: GLP-1(7-36) amide, 
GLP-1(9-36) amide, Exendine-4, and DPP 4i. The final concentration of each one was 10 nM. 
A typical plate layout is presented in Figure 5. 
  
DMSO TU
GLP1 (7-36)
GLP1 (9-36)
Exendin-4
Control
EtOH Thap
GLP1 (7-36)
GLP1 (9-36)
Exendin-4
Control
DMSO /GLP1 (7-36) /DPP-4i
DMSO /DPP-4i
TU /DPP-4i-
EtOH /DPP-4i
Thap /DPP-4i
Thap /GLP1 (7-36) /DPP-4i
TU /GLP1 (7-36) /DPP-4i
GLP1 (7-36) /DPP-4i
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Outline for the incubation of 3T3-L1 adipocytes in the presence of substances. 
2.3 Assessment of adipokines in supernatants 
 
Differentiated 3T3-L1 adipocytes were incubated in medium containing the appropriate 
substances (as indicated in Figure 5) for 5 hours. After washing with PBS (3 times) cells were 
incubated in Kreb’s Ringer buffer (1% BSA) with substance for 90 minutes. Supernatants 
were collected and marked as “c1”. c1 presumably represents an early and mild condition of 
ER stress. Then supernatants were replaced by DMEM (1.0 g/L D-glucose), 2% FCS and 
respective substances for 20 hours. These supernatants were collected as “c2”. Finally, after 
three washes in PBS the cells were incubated in Kreb’s Ringer buffer containing 1% BSA and 
respective substances for another 90 minutes (“c3”). c2 should represent a phase with 
pronounced ER stress. After the collection of c3 the cells were washed in ice cold PBS three 
times and lysed. The induction of ER stress and the action of incretins were confirmed by 
Western blotting. Concentrations of adiponectin, leptin, cytokine-induced neutrophil 
chemoattractant (KC) and IL-6 were determined using multiplex panels from Linco Research 
(Labodia, Switzerland). In c3, cells already suffer from ER stress for an extended period of  
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time. This phase might hence be characterized by secondary effects.  
 
2.4 Cell lysis and protein determination 
 
After washing with ice cold PBS, cells were lysed in lysis buffer (50 mM HEPES pH 7.5, 140 
mM NaCl, 1 mM PMSF, 0.5% Triton X-100, 10 mM NaF, 1 mM Na2H2P2O7, 1 mM Na2O4V, 
3 μg/ml aprotinin, 3 μg/ml leupeptin) and incubated at 4 °C for 30 minutes with constant 
shaking. Lysates were transferred to Eppendorf tubes and centrifuged at 15,000 g for 10 
minutes at 4 °C. Supernatants were transferred into fresh tubes and protein concentration was 
determined using the bicinchoninic acid (BCA) protein assay kit (Pierce). 
 
2.5 Immunoblotting 
 
Equal amounts of protein were loaded and separated on SDS-PAGE gels (NuPAGE, 
Invitrogen) and transferred onto PVDF membranes. After blocking with 2% non-fat milk 
(BioRad) in TBST (10 mM Tris-HCL, pH 7.4, 150 mM NaCl, 0.05 % (v/v) Tween 20) 
membranes were incubated with indicated primary and secondary antibodies either at room 
temperature for 1 hour or overnight at 4 °C. Immuno-reactive proteins were visualized by the  
 
Lumi-Light Western Blotting Substrate (Roche) using a LAS-3000 imaging system (Fuji). 
Equal loading and transfer was confirmed with an antibody against actin. 
 
2.6 Antibodies 
 
Target Species Dilution Catalogue 
Number 
Company 
Grp78 Rabbit 1:1000 sc-13968 Santa Cruz Biotechnology 
Phospho-PKB (Ser473) Rabbit 1:1000 cs 9271 Cell Signaling 
PKB Mouse 1:1000 610861 BD Bioscience 
Phospho- CREB (Ser133) Rabbit 1:1000 cs9198 Cell Signaling 
Phospho-Tyrosine Mouse 1:750 05.321 Upstate 
Insulin receptor β chain (C-19) Rabbit 1:1000 Sc-711 Santa Cruz Biotechnology 
Table 2: Primary antibodies 
 
Target Species Isotype Dilution Catalogue 
Number 
Company 
Mouse Goat IgG 1:3000 sc-2005 Santa Cruz 
Biotechnology 
Rabbit Goat IgG 1:3000 170-6515 BioRad 
 
Table 3:  Secondary antibodies 
 
 
2.7 Statistical Analysis 
Data are expressed as mean ± SEM unless noted otherwise and were analyzed by unpaired 
two-sided Student's t-test or by Anova, where appropriate. p < 0.05 was considered significant.  
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3 Results 
 
3.1 Introduction of ER stress and the action of incretins 
 
Expression of the ER stress marker Grp78 was assessed by Western blotting to confirm the 
induction of ER stress. We also assessed expression of the insulin receptor (IRβ) and 
phosphorylation of PKB and CREB by Western blotting (Figure 6). Both ER stress inducers, 
TU (blocks glycosylation) and Thap (disrupts ER Ca2+ homeostasis), significantly induced ER 
stress. Incretins did not affect the expression of the ER stress marker Grp78. No difference 
was observed in expression or phosphorylation of CREB, but overall basal phosphorylation of 
CREB was always high. Sitagliptin reduced the expression of insulin receptor under 
homeostasis. We also found that tharpsigargin could enhance CREB phosphorylation 
significantly. PKB expression and phosphorylation were not affected by incretins or Dpp-4i. 
 
 
 
 
 
 
 
 
IR β
Grp78
pPKB
pCREB
PKB
GLP -1 (7 -36)
GLP -1 (9 -36)
Exendin -4
DPP -4 i
+ 
+ 
+ 
+ + 
+ + 
+ 
+ 
+ +
+ +
+
+
+
+ 
+ 
+ 
+ +
+
+
+
DMSO TU [10 μg/ml] E Thap [600 nM] 
Figure 6: Induction of ER stress and incretins in 3T3-L1 adipocytes.  
Differentiated 3T3-L1 adipocytes were incubated in the presence of TU or Thap as indicated, and the 
supernatants were collected as mentioned. After the third phase collection, cells were washed three times with 
PBS. Expression of Grp78/BiP, IRβ activation and expression of PKB and CREB were assessed in lysates by 
Western blotting.  
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3.2 ER stress and the secretion of adipokines  
 
The accumulation of adiponectin, KC, IL-6, TNF-α and leptin was assessed (Figure 7). 
Unexpectedly, we were not able to detect TNF-α. Both tunicamycin and thapsigargin reduced 
adiponectin secretion significantly at c2 and c3 phases. In c1, the reduction was already 
visible, but not significant (Figure 7 A). Inflammatory cytokines KC (Figure 7 B) and IL-6 
(Figure 7 C) were increased under ER stress. The effect of Thap was always stronger 
compared to TU. ER stress regulated the secretion of leptin in a time-dependent manner, 
increasing it at c1 and c3 phases but reducing it at c2 phase. 
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 3.3 GLP-1(7-36)  
 
GLP-1(7-36) induced the secretion of adiponectin up to three times under homeostasis at c2 
(Figure 8 A, DMSO 199 81 pg/ml vs. DMSO/GLP-1 (7-36) 628± ± 358 pg/ml (n=4, 
P=0.0361)). It did not change adiponectin levels under either TU- or Thap-induced ER stress 
(Figure 8 B, TU 562 356 pg/ml (n=5) vs. TU/GLP-1(7-36) 579± ±325 pg/ml (n=5). Figure 8 
D, Thap 424 197 pg/ml (n=5) vs. Thap/GLP-1(7-36) 230± ±145 pg/ml (n=5)). At c2, GLP-
1(7-36) increased KC under homeostasis (two fold) but under ER stress it had the opposite 
effect and attenuated the ER stress-induced elevation of KC down to control levels (Figure 9, 
DMSO 1239 454 pg/ml vs. DMSO/GLP-1(7-36) 2497± ±1635 pg/ml (n=5), p=0.0467. TU 
4473 3839 pg/ml (n=4) vs. TU/GLP-1(7-36) 1884 1412 pg/ml (n=5)).  ± ±
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                   Figure 8: GLP-1(7-36) and Exendin-4 increase adiponectin secretion in c2 phase.  
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                                                  Figure 9: The role of GLP-1 (7-36) in KC secretion of adipocytes. 
 
3.4 Exendin-4 
 
Exendin-4 exerted similar effect as GLP-1(7-36) and increased adiponectin and KC secretion 
at c2 phase (Figure 8 and Figure 10). It increased the accumulation of adiponectin up to 3 
times under homeostasis (DMSO 199 81 pg/ml (n=4) vs. DMSO/Exendin-4 669± ±364 
pg/ml (n=4), p=0.0345) but had no influence under ER stress. Furthermore, Exendin-4 
increased KC under homeostasis already at c1 phase (Figure 13 A, DMSO 24±9 pg/ml (n=5) 
vs. DMSO/Exendin-4 59±42 pg/ml (n=5), p=0.0143) and, as GLP-1(7-36), also at c2 phage 
(Figure 10 A, DMSO 1239 454 pg/ml (n=5) vs. DMSO/Exendin-4 3789± ±2706 pg/ml 
(n=5), p=0.0044). Exendin-4 significantly reduced KC under ER stress at c2 phase (Figure 10 
B, TU 4473 3839 pg/ml (n=4) vs. TU/Exendin-4 1625± ±685 pg/ml (n=5), p=0.0094. Thap 
16120 11940 pg/ml (n=4) vs. Thap/Exendin-4 3019 1307 pg/ml (n=4), p=0.0044).  ± ±
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       Figure 10: The role of Exendin-4 in KC secretion in c2. 
3.5 GLP-1(9-36)  
 
Under homeostasis, GLP-1(9-36) increased the accumulation of adiponectin production 
2.7/2.8 times under homeostasis (DMSO/Ethanol) (Figure 11 A, DMSO 1.1±0.6 μg/ml (n=5) 
vs. DMSO/GLP-1(9-36) 3 2 μg/ml (n=4). Ethanol 1.2± ±0.8 μg/ml (n=5) vs. Ethanol/GLP-
1(9-36) 3.4±2 μg/ml (n=5), p=0.0486) but had no effect on adiponectin accumulation under 
ER stress at c2 phase (Figure 11 B, TU 0.56 0.3 μg/ml (n=5) vs. TU/GLP-1(9-36) 0.57± ±
0.33 μg/ml (n=5). Thap 0.4 0.19 μg/ml (n=4) vs. Thap/GLP-1(9-36) 0.26± ±0.16 μg/ml 
(n=5)). On the other hand, it greatly increased KC levels at c2 under homeostasis up to 100 
times compared to DMSO control (Figure 12 A, DMSO 0.029± 0.01 μg/ml (n=5) vs. 
DMSO/GLP-1 (9-36) 2.03±2. μg/ml (n=5), p<0.0001) and 5 times compared to the Ethanol 
control (Figure 12 C, Ethanol 0.02 0.01 μg/ml (n=5) vs. Ethanol/GLP-1 (9-36) 0.1± ±0.1 
μg/ml (n=5), p=0.0041). Further more, it counteracted the accumulation of KC under ER 
stress at c2 (Figure 12 B, TU 0.9 0.9 μg/ml (n=4) vs. TU/GLP-1(9-36) 0.41± ±0.4 μg/ml 
(n=5). Figure 12 D, Thap 4.7 4.6 μg/ml (n=5) vs. Thap/GLP-1(9-36) 0.056± ±0.04 μg/ml 
(n=5), p<0.0001).  
 - 27 - 
 *** p=0.0486
DM
SO
DM
SO
/ G
LP
-1(
9-3
6) E 
E/
 G
LP
-1(
9-3
6)
0
2
4
6
8
μg
/m
l
TU
 
TU
/ G
LP
-1(
9-3
6) 
Th
ap
Th
ap
/G
LP
-1(
9-3
6)
0
0.2
0.4
0.6
0.8
1
pg
/m
l
A B
Adiponectin
c2 c2
 
 
 
 
 
 
 
 
 
          Figure 11: The role of GLP-1(9-36) in adiponectin accumulation in c2. 
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           Figure 12: The role of GLP-1(9-36) in KC accumulation in c2. 
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3.6 DPP-4i (des-fluoro-sitagliptin)  
 
DPP-4 inhibitors were designed to stabilise endogenous GLP-1(7-36). In our experiments, 
DPP-4i consistently increased pro-inflammatory factors in all three phases. Early in the c1 
phase, DPP-4i increased KC under both homeostasis and ER stress (Figure 13 A, DMSO 24
±9 pg/ml (n=5) vs. DMSO/DPP-4i 55±34 pg/ml (n=5), p=0.0293. Figure 13 B, TU 117±
80 pg/ml vs. TU/DPP-4i 518±469 pg/ml (n=5), p=0/0048). At c2 (Figure 14) and c3 (Figure 
15) phases, not only KC (Figure 14 C, Figure 15 C) but also IL-6 (Figure 14 A and Figure 15) 
were increased by DPP-4i under homeostasis. Under ER stress accumulation of KC in the 
presence of DPP4i was different in the different phases. At c2 phase, DPP-4i did not further 
increase KC (Figure 14 D), but at c1 and c3, KC level was significantly increased further 
(Figure 15 D, TU 20+-5 pg/ml (n=5) vs. TU/DPP-4i 46+-21 pg/ml (n=5), p=0.0187. Figure 15 
E, Thap 386+-295 pg/ml (n=4) vs. Thap/DPP-4i 27520+-26710 pg/ml (n=5), p<0.0001).   
To further analyse the effects of DPP-4i and GLP-1(7-36), we combined the two substances 
(Figure 16). The only changes observed were in accumulation of IL-6 and KC, relative to 
cells incubated in the presence of each compound alone. Synergism between the two 
compounds was generally not obvious. E.g.: in c2 GLP-1(7-36) alone reduced ER stress-
induced accumulation of KC (Figure 9), while DPP4i even further increased it (Figure 15 D). 
The combination of DPP4i and GLP-1(7-36) resulted in decreased accumulation of KC in c2 
(Figure 16 E), as with GLP-1(7-36) alone. The same was true with respect to IL-6 
accumulation in c2 under ER stress. 
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   Figure 13: DPP-4i and KC accumulation in c1. 
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   Figure 14: DPP-4i and the accumulation of IL-6 and KC in c2.  
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4 Discussion 
 
The change in adipokine secretion during obesity plays an important role in insulin resistance 
and diabetes development [122, 123]. Incretins are new drug targets to improve blood glucose 
homeostasis in diabetes. The first incretin-based anti-diabetic treatment (exenatide; Byetta) 
was approved in 2005 as an adjunctive therapy in diabetic patients in whom sulfonylurea, 
metformin or both had failed [124]. Dipeptidyl peptidase 4 inhibitors are currently used in the 
clinic for the treatment of type 2 diabetes and show promising results in the improvement of 
glucose homeostasis. However, long-term effects have not been described yet.  
In the presented thesis the role of incretins, incretin analogue and Sitagliptin in adipokine 
secretion was tested under homeostasis or ER stress.  
 
4.1 ER stress increases pro-inflammatory cytokines and reduces adiponectin secretion  
 
Previous work showed that ER stress changes adipokine secretion from adipocytes [125]. 
Adiponectin was strongly reduced but IL-6 significantly increased. In this study, we found 
that also KC production by adipocytes is elevated under ER stress. Our results fit well to the 
hypothesis that ER stress triggers accumulation of inflammatory factors and at the same time 
reduces anti-diabetic factors. Although there were already studies showing that ER stress [77] 
and cytokines [17] could both contribute to the development of insulin resistance in obesity, 
there were only few reports [126, 127] that link ER stress with cytokine production. Our study 
confirms and extends the notion that obesity-induced ER stress can result in adipokine 
secretion resembling the inflammatory situation often observed in obesity and insulin 
resistance.  
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4.2 GLP-1(7-36), Exendin-4 and GLP-1(9-36) regulate adipokine secretion in a similar 
manner 
 
It is well established that GLP-1(7-36) and Exendin-4 act synergistically to improve insulin 
sensitivity in adipocytes [107, 111]. Our finding that GLP-1(7-36) and Exendin-4 increased 
adiponectin secretion under homeostasis (Figure 8, 10 and 11) supports this notion and offers 
an attractive mechanistic explanation. On the other hand, however, KC secretion was also 
elevated. Under ER stress, GLP-1(7-36) and Exendin-4 did not influence adiponectin but 
reduced KC levels, in line with the beneficial effects of incretins under obesity. The 
observation that both, GLP-1(7-36) and Exendin-4, showed similar effects indicates that GLP-
1 receptor signalling might influence the secretion of adipokines.  
Some studies suggested that GLP-1(9-36) may be an antagonist of GLP-1(7-36), however, 
other studies could not confirm this hypothesis [128]. It is still unclear whether GLP-1(9-36) 
is a GLP-1 receptor antagonist or even an agonist. Our finding that GLP-1(9-36) affects the 
secretion of adiponectin and KC in the same manner as GLP-1(7-36) (Figure 11, 13) is in 
support of an agonistic role of GLP-1(9-36) . 
 
4.3 Sitagliptin induces inflammatory cytokines independent of GLP-1(7-36) 
 
Circulating GLP-1(7-36) is rapidly degraded to GLP-1(9-36) by DPP-4. In the presence of the 
inhibitor of DPP-4, we expected to stabilize GLP-1(7-36). But synergism between the two 
compounds was not obvious. To our surprise, Sitagliptin significantly induced the 
accumulation of inflammatory factors but did not modulate adiponectin as found for GLP-
1(7-36). It also did not change adiponectin in the presence of GLP-1(7-36) (data not shown). 
Changes observed in accumulation of IL-6 and KC induced by combination of Sitagliptin and 
GLP-1(7-39) is relative to cells incubated in the presence of each compound alone. E.g.: cells 
incubated simultaneously with GLP-1(7-36) and Sitagliptin (Figure 16) showed elevated 
inflammatory cytokines even in the c1 phase as if only using Sitagliptin. But under ER stress 
IL-6 was not further increased, KC was even decreased at c2 in the presence of GLP-1(7-36) 
or Exendin-4 alone, respectively. These results indicate that the effects of Sitagliptin on 
adipokine secretion are independent of blocking the degradation of GLP-1(7-36). It was 
known that DPP-4 not only has enzymatic function to cleave substrates such as GLP-1(7-36)  
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or GIP, but also acts as membrane receptor that can recruit other proteins for signal 
transduction into the cells [129, 130]. Effects of Sitagliptin independent of incretin action can 
hence not be excluded. 
Previous studies have shown that DPP-4 inhibits cytokine production [121]. This finding is in 
line with our own observation and could explain the increased production of KC and IL-6 in 
the presence of Sitagliptin. Furthermore, a clinical study by Dr. Anastassios G. Pittas has 
shown that patients treated with Sitagliptin show an increased risk of urinary tract infection 
and nasopharyngitis [131]. This further supports the notion that DPP-4 inhibitors could be 
immuno-modulatory.  
Our observation that Sitagliptin decreases the expression of insulin receptor and increases 
cytokine production raises the question whether Sitagliptin could induce insulin resistance. 
Further studies are required to confirm our observation. However, no decreased insulin 
sensitivity in patients treated with Sitagliptin has been reported so far. 
 
Finally, it is hoped that this thesis has provided new useful insights into the possible 
importance of incretins for adipocyte biology. Although GLP-1(7-36) and Sitagliptin appear 
as effective agents for achieving blood glucose control, our data imply that they affect adipose 
tissue secretory function which might lead to yet undetected long-term systemic effects. 
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